Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...
Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...
Seattle, Wash., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Greater Good Charities is teaming up with Boehringer Ingelheim for the global nonprofit’s annual Shelter Bowl event. The event will donate ...
ExpressionEdits in Cambridge has clinched unspecified riches from global pharmaceutical company Boehringer Ingelheim through ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
The Campaign will Donate Millions of Meals and Thousands of Doses of NexGard® PLUS (afoxolaner, moxidectin, and pyrantel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback